Angiogenesis in cancer and other diseases
The DOI matches its Crossref record; 71 of the 72 references it cites were found in a registry or an index.
Abstract
Pathological angiogenesis is a hallmark of cancer and various ischaemic and inflammatory diseases. Concentrated efforts in this area of research are leading to the discovery of a growing number of pro- and anti-angiogenic molecules, some of which are already in clinical trials. The complex interactions among these molecules and how they affect vascular structure and function in different environments are now beginning to be elucidated. This integrated understanding is leading to the development of a number of exciting and bold approaches to treat cancer and other diseases. But owing to several unanswered questions, caution is needed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The presence of vascularization is one of the landmarks of tumor environments [57,180].”
From The Tumor-on-Chip: Recent Advances in the Development of Microfluidic Systems to Recapitulate the Physiology of Solid Tumors (2019) · cites this paper as [180]
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486 · cited 1×
“This hypothesis formed the basis of the discovery of angiostatin, endostatin, vasculostatin and other endogenous inhibitors of angiogenesi”
BackgroundMechanisms of angiogenesis and arteriogenesis
Carmeliet, P. (2000) · Nature Medicine · doi:10.1038/74651 · Cited by 4,162 · cited 1×
“We now know there are various molecular players involved in these different mechanisms of vascular growt”
BackgroundSelf-citationAbnormal blood vessel development and lethality in embryos lacking a single VEGF allele
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., et al. (1996) · Nature · doi:10.1038/380435a0 · Cited by 4,117
Self-citationO'Reilly, M. (1994) · Cell · doi:10.1016/0092-8674(94)90200-3 · Cited by 3,345 · cited 1×
“This hypothesis formed the basis of the discovery of angiostatin, endostatin, vasculostatin and other endogenous inhibitors of angiogenesi”
BackgroundRole of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502 · cited 1×
“However, caution is warranted as these hypoxia-inducible factors could also control cell deat”
BackgroundSelf-citationRegulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438
Self-citationCancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model
Arap, W., Pasqualini, R., & Ruoslahti, E. (1998) · Science · doi:10.1126/science.279.5349.377 · Cited by 2,054 · cited 1×
“In vivo selection of phage display libraries has recently yielded peptides (for example, amino-acid sequences RGD and NGR) that preferentially recognize vessels in subcutaneous tumours in mic”
BackgroundOpenings Between Defective Endothelial Cells Explain Tumor Vessel Leakiness
Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., & McDonald, D. M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65006-7 · Cited by 1,689
Self-citationHelmlinger, G., Yuan, F., Dellian, M., & Jain, R. K. (1997) · Nature Medicine · doi:10.1038/nm0297-177 · Cited by 1,628
Self-citation
Research works printed but not linked: 8
- Greenblatt, M. & Shubik, P. Tumor angiogenesis: transfilter diffusion studies in the hamster by the transparant chamber technique. J. Natl Cancer Inst. 41, 111–124 (1968).
- Ehrmann, R. L. & Knoth, M. Choriocarcinoma: transfilter stimulation of vasoproliferation in the hamster cheek pouch studied by light and electron microscopy. J. Natl Cancer Inst. 41, 1329 –1341 (1968).
- Folkman, J. in Cancer Medicine (eds Holland, J. F. et al.) 132– 152 (Decker, Ontario, Canada, 2000).
- Chang, Y. S. et al. Abundance of neoplastic cells in vessel walls of human tumor xenografts. Proc. Am. Assoc. Cancer Res. (in the press).
- Seljelid, R., Jozefowski, S. & Sveinbjornsson, B. Tumor stroma. Anticancer Res. 19, 4809–4822 (1999).
- Buschmann, I. & Schaper, W. The pathophysiology of the collateral circulation (arteriogenesis). J. Pathol. 190, 338–342 (2000). · doi:10.1002/(sici)1096-9896(200002)190:3<338::aid-path594>3.0.co;2-7
- Carmeliet, P. & Collen, D. Transgenic mouse models in angiogenesis and cardiovascular disease. J. Pathol. 190, 387–405 (2000). · doi:10.1002/(sici)1096-9896(200002)190:3<387::aid-path595>3.0.co;2-r
- Tsuzuki, Y. et al. VEGF modulation by targeting HIF-1alpha/HRE/VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Res. (in the press).
Cited by
Items 101–200 of 1,084
The role of hypoxia-inducible factors in tumorigenesis
Rankin, E. B., & Giaccia, A. J. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.21 · Cited by 806
“progression since the supply of oxygen and nutrients becomes limited in tumor cells that are located more than 100mm away from a blood vessel.(60) The ability of tumor cells”
BackgroundGenetic determinants of cancer metastasis
Nguyen, D. X., & Massagué, J. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2101 · Cited by 801
Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis
Heeschen, C., Jang, J. J., Weis, M., Pathak, A., Kaji, S., Hu, R. S., Tsao, P. S., Johnson, F. L., & Cooke, J. P. (2001) · Nature Medicine · doi:10.1038/89961 · Cited by 800
“gif" NDATA ITEM> ]> Angiogenesis is a complex, combinatorial process that is regulated by a balance between pro- and anti-angiogenic molecule”
BackgroundWedge, S. R., Ogilvie, D., Dukes, M., Kendrew, J., Chester, R., Jackson, J. A., Boffey, S. J., Valentine, P. J., Curwen, J., Musgrove, H. L., et al. (2002) · PubMed · Cited by 798
Schoppmann, S. F., Birner, P., Stöckl, J., Kalt, R., Ullrich, R., Caucig, C., Kriehuber, E., Nagy, K., Alitalo, K., & Kerjaschki, D. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64255-1 · Cited by 794
Advances in polymeric micelles for drug delivery and tumor targeting
Kedar, U., Phutane, P., Shidhaye, S., & Kadam, V. (2010) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2010.05.005 · Cited by 791
Dejana, E., Tournier-Lasserve, E., & Weinstein, B. M. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.01.004 · Cited by 788
Cellular abnormalities of blood vessels as targets in cancer
Baluk, P., Hashizume, H., & McDonald, D. M. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.12.005 · Cited by 781
“The dominant process of vessel growth is angiogenesis by sprouting of existing vessels [4,5] (Figure 2a).”
BackgroundMichiels, C. (2003) · Journal of Cellular Physiology · doi:10.1002/jcp.10333 · Cited by 773
“This angiogenesis process requires many interactions that must be tightly regulated in a spatial and temporal manner (Carmeliet, 2000; Carmeliet and Jain, 2000; Saaristo et al., 2000; Liekens et al., 2001).”
BackgroundAlexander, M. R., & Owens, G. K. (2012) · Annual Review of Physiology · doi:10.1146/annurev-physiol-012110-142315 · Cited by 773
Neurovascular mechanisms of Alzheimer's neurodegeneration
Zlokovic, B. V. (2005) · Trends in Neurosciences · doi:10.1016/j.tins.2005.02.001 · Cited by 770
URBICH, C., AICHER, A., HEESCHEN, C., DERNBACH, E., HOFMANN, W., ZEIHER, A., & DIMMELER, S. (2005) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2005.07.003 · Cited by 741
“All factors have been described as pro-angiogenic growth factors (for review see [28]).”
BackgroundMolecular mechanisms of lymphangiogenesis in health and disease
Alitalo, K., & Carmeliet, P. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00051-x · Cited by 734
“It is now widely accepted that the switch is off when the effect of proangiogenic molecules is balanced by that of antiangiogenic molecules, and is on when the net balance is tipped in favor of angiogenesis (Carmeliet and Jain, 2000; Hanahan and Folkman, 1996).”
BackgroundInfluentialSelf-citationThe clinical role of the TME in solid cancer
Giraldo, N. A., Sanchez-Salas, R., Peske, J. D., Vano, Y., Becht, E., Petitprez, F., Validire, P., Ingels, A., Cathelineau, X., Fridman, W. H., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0327-z · Cited by 732
Mediators of vascular remodelling co-opted for sequential steps in lung metastasis
Gupta, G. P., Nguyen, D. X., Chiang, A. C., Bos, P. D., Kim, J. Y., Nadal, C., Gomis, R. R., Manova-Todorova, K., & Massagué, J. (2007) · Nature · doi:10.1038/nature05760 · Cited by 727
Hypoxia and Metabolic Adaptation of Cancer Cells
Eales, K. L., Hollinshead, K. E. R., & Tennant, D. A. (2016) · Oncogenesis · doi:10.1038/oncsis.2015.50 · Cited by 724
Specialization of tumour vasculature
Ruoslahti, E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc724 · Cited by 722
Kudo, M., Ueshima, K., Ikeda, M., Torimura, T., Tanabe, N., Aikata, H., Izumi, N., Yamasaki, T., Nojiri, S., Hino, K., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-318934 · Cited by 721
Kolluru, G. K., Bir, S. C., & Kevil, C. G. (2012) · International Journal of Vascular Medicine · doi:10.1155/2012/918267 · Cited by 720
Fibroblast Growth Factors: Biology, Function, and Application for Tissue Regeneration
Yun, Y.-R., Won, J. E., Jeon, E., Lee, S., Kang, W., Jo, H., Jang, J.-H., Shin, U. S., & Kim, H.-W. (2010) · Journal of Tissue Engineering · doi:10.4061/2010/218142 · Cited by 712
“conditions such as embryonic development, wound repair, inflammation, and tumor growth [58].”
BackgroundLee, S., Jilani, S. M., Nikolova, G. V., Carpizo, D., & Iruela-Arispe, M. L. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200409115 · Cited by 703
“In contrast, vessel formation in tumors appears much less programmed and is improvised from a limited array of stimulatory factors (Carmeliet and Jain, 2000; McDonald and Choyke, 2003).”
BackgroundTNF-α in Cancer Treatment: Molecular Insights, Antitumor Effects, and Clinical Utility
van Horssen, R., ten Hagen, T. L. M., & Eggermont, A. M. M. (2006) · The Oncologist · doi:10.1634/theoncologist.11-4-397 · Cited by 701
The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease.
Holmes, D. I. R., & Zachary, I. C. (2005) · Genome biology · doi:10.1186/gb-2005-6-2-209 · Cited by 779
“VEGF-A-driven angiogenesis has a major role in the pathogenesis of diverse human diseases, including cancer, eye disorders and rheumatoid arthritis [44].”
BackgroundThe mathematics of cancer: integrating quantitative models
Altrock, P. M., Liu, L. L., & Michor, F. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4029 · Cited by 685
Bishop, E. S., Mostafa, S., Pakvasa, M., Luu, H. H., Lee, M. J., Wolf, J. M., Ameer, G. A., He, T.-C., & Reid, R. R. (2017) · Genes & Diseases · doi:10.1016/j.gendis.2017.10.002 · Cited by 683
“In vivo, a vascular network is required for tissues to grow beyond 100e200 mm, as this is the diffusion limit of oxygen.(88) Without a vascular network, engineered tissues will have nutrient limitations resulting in incomplete tissue formation or necrosis.”
BackgroundThe many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis
Chang, C., & Werb, Z. (2001) · Trends in Cell Biology · doi:10.1016/s0962-8924(01)02122-5 · Cited by 683
Statins Have Biphasic Effects on Angiogenesis
Weis, M., Heeschen, C., Glassford, A. J., & Cooke, J. P. (2002) · Circulation · doi:10.1161/hc0602.103393 · Cited by 680
Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?
Rafii, S., Lyden, D., Benezra, R., Hattori, K., & Heissig, B. (2002) · Nature Reviews Cancer · doi:10.1038/nrc925 · Cited by 679
“Similarly, the origin of neo-vessels within the expanding tumour tissue has been the subject of intense investigatio”
BackgroundKudo, M., Kawamura, Y., Hasegawa, K., Tateishi, R., Kariyama, K., Shiina, S., Toyoda, H., Imai, Y., Hiraoka, A., Ikeda, M., et al. (2021) · Liver Cancer · doi:10.1159/000514174 · Cited by 678
Mosaic blood vessels in tumors: Frequency of cancer cells in contact with flowing blood
Chang, Y. S., di Tomaso, E., McDonald, D. M., Jones, R., Jain, R. K., & Munn, L. L. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.26.14608 · Cited by 671
Self-citationSong, M., Liu, T., Shi, C., Zhang, X., & Chen, X. (2016) · ACS Nano · doi:10.1021/acsnano.5b06779 · Cited by 662
Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy
Ushio-Fukai, M., & Nakamura, Y. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.02.044 · Cited by 651
“[6] P.”
BackgroundUnraveling the mysteries of serum albumin—more than just a serum protein
Merlot, A. M., Kalinowski, D. S., & Richardson, D. R. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00299 · Cited by 641
“doi: 10.1016/S0168-3659(99)00248-5 Matsumura, Y., and Maeda, H. (1986). A new concept for macromolecular thera-”
BackgroundInfluentialZhou, Y., McMaster, M., Woo, K., Janatpour, M., Perry, J., Karpanen, T., Alitalo, K., Damsky, C., & Fisher, S. J. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62567-9 · Cited by 640
The Platelet Lifeline to Cancer: Challenges and Opportunities
Haemmerle, M., Stone, R. L., Menter, D. G., Afshar-Kharghan, V., & Sood, A. K. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.002 · Cited by 638
Hattori, K., Heissig, B., Wu, Y., Dias, S., Tejada, R., Ferris, B., Hicklin, D. J., Zhu, Z., Bohlen, P., Witte, L., et al. (2002) · Nature Medicine · doi:10.1038/nm740 · Cited by 633
“Within the vascular endothelial growth factor (VEGF) family, VEGF-A is a potent mediator of the angiogenic switc”
BackgroundPrasad, P., Gordijo, C. R., Abbasi, A. Z., Maeda, A., Ip, A., Rauth, A. M., DaCosta, R. S., & Wu, X. Y. (2014) · ACS Nano · doi:10.1021/nn405773r · Cited by 630
“is involved in cancer cell metabolism, angiogenesis, invasion, metastasis, and apoptosis.(40) Overexpression of VEGF is a hallmark of tumor angiogenesis.”
BackgroundDefining the role of the tumor vasculature in antitumor immunity and immunotherapy
Schaaf, M. B., Garg, A. D., & Agostinis, P. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0061-0 · Cited by 629
“[6] MDSCs are a source of reactive nitrogen species that nitrate CCL-2 and tyrosines of the T-cell receptor that recruits more monocytes [7] and impedes CTL antigen recognition, [8] respectively.”
Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways
Eroles, P., Bosch, A., Alejandro Pérez-Fidalgo, J., & Lluch, A. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.11.005 · Cited by 624
“One of the main factors involved in the activation of angiogenesis is the vascular endothelial growth factor (VEGF), which operates mainly through three tyrosine kinase membrane receptors (VEGFR 1–3).(84) The tumor neovasculature is characterized by vessel excessive branching, architectural distortion, erratic blood f…”
BackgroundHuman Identification Using Finger Images
Kumar, A., & Zhou, Y. (2012) · IEEE Transactions on Image Processing · doi:10.1109/tip.2011.2171697 · Cited by 624
Chapter 2 PI3K/PTEN Signaling in Angiogenesis and Tumorigenesis
(2009) · Advances in Cancer Research · doi:10.1016/s0065-230x(09)02002-8 · Cited by 620
“Tumor angiogenesis occurs by sprouting the new vessels from preexisting blood vessels or by inserting interstitial tissue columns into the lumen of preexisting vessels (Carmeliet and Jain, 2000).”
BackgroundEnhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins
Reynolds, L. E., Wyder, L., Lively, J. C., Taverna, D., Robinson, S. D., Huang, X., Sheppard, D., Hynes, R. O., & Hodivala-Dilke, K. M. (2002) · Nature Medicine · doi:10.1038/nm0102-27 · Cited by 613
“Angiogenesis is a hallmark of cancer, as well as various ischemic diseases such as retinopathy of prematurit”
BackgroundSiemann, D. W. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.05.001 · Cited by 611
Brown, E. B., Campbell, R. B., Tsuzuki, Y., Xu, L., Carmeliet, P., Fukumura, D., & Jain, R. K. (2001) · Nature Medicine · doi:10.1038/89997 · Cited by 605
“gif" NDATA ITEM> ]> Intravital microscopy combined with green fluorescent protein (GFP) and various chronic animal window preparations has provided powerful insight into gene expression, physiological function and drug delivery in tumor”
BackgroundSelf-citationNitric Oxide: Physiological Functions, Delivery, and Biomedical Applications
Andrabi, S. M., Sharma, N. S., Karan, A., Shahriar, S. M. S., Cordon, B., Ma, B., & Xie, J. (2023) · Advanced Science · doi:10.1002/advs.202303259 · Cited by 602
Ardi, V. C., Kupriyanova, T. A., Deryugina, E. I., & Quigley, J. P. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706438104 · Cited by 602
Fernández, M., Semela, D., Bruix, J., Colle, I., Pinzani, M., & Bosch, J. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.12.011 · Cited by 600
“Although neo-angiogenesis is a common feature of most chronic inflammatory and fibrogenic disorders [12,13], hepatic angiogenesis may substantially differ from homologous processes in other organs or tissue on the basis of: (a) the rather unique phenotypic profile and functional role of activated hepatic stellate cell…”
BackgroundDelivery of Molecular and Nanoscale Medicine to Tumors: Transport Barriers and Strategies
Chauhan, V. P., Stylianopoulos, T., Boucher, Y., & Jain, R. K. (2011) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-061010-114300 · Cited by 597
Self-citationDissecting tumour pathophysiology using intravital microscopy
Jain, R. K., Munn, L. L., & Fukumura, D. (2002) · Nature Reviews Cancer · doi:10.1038/nrc778 · Cited by 595
Self-citationBos, R., van der Hoeven, J. J. M., van der Wall, E., van der Groep, P., van Diest, P. J., Comans, E. F. I., Joshi, U., Semenza, G. L., Hoekstra, O. S., Lammertsma, A. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.2.379 · Cited by 591
Taraboletti, G., D'Ascenzo, S., Borsotti, P., Giavazzi, R., Pavan, A., & Dolo, V. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64887-0 · Cited by 588
“Deregulated angiogenesis is at the basis of several pathologies, including arthritis, diabetic retinopathy, and tumor growth and metastatic dissemination.(6) Remodeling of the extracellular matrix is a crucial event during angiogenesis.”
BackgroundClassical Mathematical Models for Description and Prediction of Experimental Tumor Growth
Benzekry, S., Lamont, C., Beheshti, A., Tracz, A., Ebos, J. M. L., Hlatky, L., & Hahnfeldt, P. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003800 · Cited by 587
Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalize
Fukumura, D., & Jain, R. K. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21187 · Cited by 584
Self-citationErickson, H. K., Park, P. U., Widdison, W. C., Kovtun, Y. V., Garrett, L. M., Hoffman, K., Lutz, R. J., Goldmacher, V. S., & Blättler, W. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4489 · Cited by 584
Tumour vascularization: sprouting angiogenesis and beyond
Hillen, F., & Griffioen, A. W. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9094-7 · Cited by 583
“This process is regulated by a variety of pro- and anti-angiogenic factors, and is a prerequisite for further outgrowth of the tumour [1].”
BackgroundTherapeutic targeting of the tumor microenvironment
Joyce, J. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.024 · Cited by 582
“Another barrier results from the chaot ic nature of the tumor vasculature, as tumor vessels are dilated, leaky, and tortuous ( Carmeliet and Jain, 2000 ), which further contributes to decreased drug delivery.”
Collagen as a double-edged sword in tumor progression
Fang, M., Yuan, J., Peng, C., & Li, Y. (2014) · Tumor Biology · doi:10.1007/s13277-013-1511-7 · Cited by 580
Stabilization of atherosclerotic plaques: New mechanisms and clinical targets
Libby, P., & Aikawa, M. (2002) · Nature Medicine · doi:10.1038/nm1102-1257 · Cited by 580
“Given the probable involvement of intraplaque microvessels in leukocyte recruitment into the intima and the formation of macrophage-rich atherom”
BackgroundButler, J. M., Kobayashi, H., & Rafii, S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2791 · Cited by 578
Expression and Function of Laminins in the Embryonic and Mature Vasculature
Hallmann, R., Horn, N., Selg, M., Wendler, O., Pausch, F., & Sorokin, L. M. (2005) · Physiological Reviews · doi:10.1152/physrev.00014.2004 · Cited by 574
“Since most information is available for the role of VEGF-A and its receptor VEGFR2 (also known as flk-1) we describe only this interaction here and its function on initiation of vessel formation and the series of molecular and cellular events that lead to vessel maturation (24, 25, 144, 200).”
BackgroundIntegrins: roles in cancer development and as treatment targets
Jin, H., & Varner, J. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601576 · Cited by 574
“…and also plays a key role in the pathological development of solid tumour cancers, haemangiomas, diabetic retinopathy, age-related macular degeneration, psoriasis, gingivitis, rheumatoid arthritis and possibly osteoarthritis and inflammatory bowel disease (reviewed in Carmeliet and Jain, 2000).”
BackgroundGenetic and biological hallmarks of colorectal cancer
Li, J., Ma, X., Chakravarti, D., Shalapour, S., & DePinho, R. A. (2021) · Genes & Development · doi:10.1101/gad.348226.120 · Cited by 573
Biomarkers of response and resistance to antiangiogenic therapy
Jain, R. K., Duda, D. G., Willett, C. G., Sahani, D. V., Zhu, A. X., Loeffler, J. S., Batchelor, T. T., & Sorensen, A. G. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.63 · Cited by 572
“estimating kinetic parameters from dynamic contrast‐enhanced T(1)‐weighted Mri of a diffusable tracer: standardized quantities and symbols.”
BackgroundSelf-citationEelen, G., de Zeeuw, P., Treps, L., Harjes, U., Wong, B. W., & Carmeliet, P. (2018) · Physiological Reviews · doi:10.1152/physrev.00001.2017 · Cited by 572
Self-citationFlavonoids as prospective compounds for anti-cancer therapy
Ravishankar, D., Rajora, A. K., Greco, F., & Osborn, H. M. I. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.10.004 · Cited by 572
The biology of brain metastases—translation to new therapies
Eichler, A. F., Chung, E., Kodack, D. P., Loeffler, J. S., Fukumura, D., & Jain, R. K. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.58 · Cited by 567
“Angiogenesis The growth and proliferation of primary and metastatic tumors is dependent on the establishment of an adequate blood supply”
BackgroundSelf-citationBlood vessel segmentation algorithms — Review of methods, datasets and evaluation metrics
Moccia, S., De Momi, E., El Hadji, S., & Mattos, L. S. (2018) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2018.02.001 · Cited by 567
HCC and angiogenesis: possible targets and future directions
Zhu, A. X., Duda, D. G., Sahani, D. V., & Jain, R. K. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.30 · Cited by 564
“VEGF expression is regulated by oncogenic gene mutations, hormones, cytokines and various signaling molecules (nitric oxide, MAP kinases)”
BackgroundSelf-citationImproving immune–vascular crosstalk for cancer immunotherapy
Huang, Y., Kim, B. Y. S., Chan, C. K., Hahn, S. M., Weissman, I. L., & Jiang, W. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.145 · Cited by 563
Stylianopoulos, T., Munn, L. L., & Jain, R. K. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2018.02.005 · Cited by 563
Self-citationHamano, Y., Zeisberg, M., Sugimoto, H., Lively, J. C., Maeshima, Y., Yang, C., Hynes, R. O., Werb, Z., Sudhakar, A., & Kalluri, R. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00133-8 · Cited by 559
“…in exposure of endothelial cells to different isoforms, degradation products, and molecular structures of VBM molecules in a short period of time (Carmeliet and Jain, 2000; Czubayko et al., 1997; Eliceiri et al., 1999; Ferrara, 2000; Folkman, 2001; Folkman and Kalluri, 2003; Hanahan and…”
BackgroundHeterotypic Signaling between Epithelial Tumor Cells and Fibroblasts in Carcinoma Formation
Elenbaas, B., & Weinberg, R. A. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5133 · Cited by 558
Bioactive Benzofuran derivatives: A review
Khanam, H., & Shamsuzzaman (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.11.039 · Cited by 554
Photoacoustic clinical imaging
Steinberg, I., Huland, D. M., Vermesh, O., Frostig, H. E., Tummers, W. S., & Gambhir, S. S. (2019) · Photoacoustics · doi:10.1016/j.pacs.2019.05.001 · Cited by 553
“Since various abnormal states cause changes in tissue composition, such as vascular fat deposition in atherosclerotic plaques [160] or angiogenesis in cancer development [161], PAI has the potential to visualize and quantify these changes in comparison with the healthy surrounding tissue.”
BackgroundNonlinear modelling of cancer: bridging the gap between cells and tumours
Lowengrub, J. S., Frieboes, H. B., Jin, F., Chuang, Y.-L., Li, X., Macklin, P., Wise, S. M., & Cristini, V (2010) · Nonlinearity · doi:10.1088/0951-7715/23/1/r01 · Cited by 553
“In addition, chaotic angiogenesis leads to heterogeneous perfusion in the tumour that also may be responsible for regression of parts of the vascular network and necrosis of tumour cells [101, 407].”
The tumour microenvironment in B cell lymphomas
Scott, D. W., & Gascoyne, R. D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3774 · Cited by 552
The stroma reaction myofibroblast: a key player in the control of tumor cell behavior
Desmouliere, A., Guyot, C., & Gabbiani, G. (2004) · The International Journal of Developmental Biology · doi:10.1387/ijdb.041802ad · Cited by 551
“Although the role of inflammatory cells and endothelial cells in tumor immunity (Coussens and Werb, 2002) and of neoangiogenesis in tumor progression (Carmeliet and Jain, 2000) have been well described, the role of (myo)fibroblasts in cancer evolution has not been fully elucidated at present.”
BackgroundMatsui, J., Yamamoto, Y., Funahashi, Y., Tsuruoka, A., Watanabe, T., Wakabayashi, T., Uenaka, T., & Asada, M. (2008) · International Journal of Cancer · doi:10.1002/ijc.23131 · Cited by 551
(2002) · PubMed · Cited by 550
Mathematical Models of Avascular Tumor Growth
Roose, T., Chapman, S. J., & Maini, P. K. (2007) · SIAM Review · doi:10.1137/s0036144504446291 · Cited by 550
“This hypothesis is that, in order to grow large, tumors need to obtain their own blood vessels and therefore must recruit vessels from the host vasculature through angiogenesis [6].”
Park, H. J., Griffin, R. J., Hui, S., Levitt, S. H., & Song, C. W. (2012) · Radiation Research · doi:10.1667/rr2773.1 · Cited by 549
“the microvasculature of slowly growing human tumors exhibit a thin layer of smooth muscle similar to the capillaries of normal tissues (13).”
BackgroundSpratlin, J. L., Cohen, R. B., Eadens, M., Gore, L., Camidge, D. R., Diab, S., Leong, S., O'Bryant, C., Chow, L. Q. M., Serkova, N. J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7537 · Cited by 549
“Angiogenesis is regulated principally by interactions between vascular endothelial growth factors (VEGFs) and VEGF receptors (VEGFRs) and plays a key role in cancer growth and metastasis.(1-5) VEGF-A is the central regulator of tumor angiogenesis, endothelial proliferation, permeability, and survival.”
BackgroundDe Palma, M., Venneri, M. A., Roca, C., & Naldini, L. (2003) · Nature Medicine · doi:10.1038/nm871 · Cited by 549
“jpg" NDATA ITEM> ]> Angiogenic tumor vessels are promising targets for the activity and the selective delivery of cancer therapeutic”
BackgroundThe impact of hypoxia on tumor-associated macrophages
Henze, A.-T., & Mazzone, M. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84427 · Cited by 546
“Additionally, hypoxic cells are subjected to selection pressure, with the most aggressive cells surviving these hostile growth conditions and driving tumor growth (36).”
Emerging role of adipose tissue hypoxia in obesity and insulin resistance
Ye, J. (2009) · International Journal of Obesity · doi:10.1038/ijo.2008.229 · Cited by 543
Biology of vascular endothelial growth factors
Roy, H., Bhardwaj, S., & Ylä-Herttuala, S. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.03.087 · Cited by 537
“Role of VEGF in tumor angiogenesis, especially in lung, gastrointestinal, ovarian and breast cancers has been investigated and tumor angiogenesis has become a potential target for cancer therapy [56].”
BackgroundSonveaux, P., Copetti, T., De Saedeleer, C. J., Végran, F., Verrax, J., Kennedy, K. M., Moon, E. J., Dhup, S., Danhier, P., Frérart, F., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033418 · Cited by 536
“On the other hand, the angiogenic switch, corresponding to the initiation of vascular extension, aims at increasing oxygen and nutrient supply to hypoxic tumor sites [6].”
BackgroundLipid‐based nanoparticles for contrast‐enhanced MRI and molecular imaging
Mulder, W. J. M., Strijkers, G. J., van Tilborg, G. A. F., Griffioen, A. W., & Nicolay, K. (2006) · NMR in Biomedicine · doi:10.1002/nbm.1011 · Cited by 535
“Angiogenesis, the formation of new blood vessels from pre-existing blood vessels, is a sequence of events that is key in many pathological processes (14,82,83).”
BackgroundGupta, K., Kshirsagar, S. A., Chang, L., Schwartz, R. E., Law, P., Yee, D., & Hebbel, R. P. (2002) · PubMed · Cited by 535
Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis
Sawamiphak, S., Seidel, S., Essmann, C. L., Wilkinson, G. A., Pitulescu, M. E., Acker, T., & Acker-Palmer, A. (2010) · Nature · doi:10.1038/nature08995 · Cited by 534
Improving drug delivery to solid tumors: Priming the tumor microenvironment
Khawar, I. A., Kim, J. H., & Kuh, H.-J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.018 · Cited by 533
Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2
Plotkin, S. R., Stemmer-Rachamimov, A. O., Barker, F. G., Halpin, C., Padera, T. P., Tyrrell, A., Sorensen, A. G., Jain, R. K., & di Tomaso, E. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902579 · Cited by 532
Self-citationHSP90 as a new therapeutic target for cancer therapy: the story unfolds
Maloney, A., & Workman, P. (2002) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2.1.3 · Cited by 531
The tumor microenvironment and its contribution to tumor evolution toward metastasis
Lorusso, G., & Rüegg, C. (2008) · Histochemistry and Cell Biology · doi:10.1007/s00418-008-0530-8 · Cited by 531
“The formation of a tumor-associated (angiogenic) vasculature is a stromal reaction essential for tumor progression (Carmeliet and Jain 2000; Kerbel 2008).”
BackgroundGPX4: The hub of lipid oxidation, ferroptosis, disease and treatment
Liu, Y., Wan, Y., Jiang, Y., Zhang, L., & Cheng, W. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188890 · Cited by 528
Statin effects beyond lipid lowering—are they clinically relevant?
Bonetti, P. (2003) · European Heart Journal · doi:10.1016/s0195-668x(02)00419-0 · Cited by 527
“121 The process of angiogenesis is very complex and depends on the interaction of several pro-and anti-angiogenic molecules to form functional vessels.”
PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis
Cao, R., Björndahl, M. A., Religa, P., Clasper, S., Garvin, S., Galter, D., Meister, B., Ikomi, F., Tritsaris, K., Dissing, S., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.034 · Cited by 527
Kriehuber, E., Breiteneder-Geleff, S., Groeger, M., Soleiman, A., Schoppmann, S. F., Stingl, G., Kerjaschki, D., & Maurer, D. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.797 · Cited by 525
Overcoming barriers in photodynamic therapy harnessing nano-formulation strategies
Xie, J., Wang, Y., Choi, W., Jangili, P., Ge, Y., Xu, Y., Kang, J., Liu, L., Zhang, B., Xie, Z., et al. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01370f · Cited by 522
He, Y., Kozaki, K.-I., Karpanen, T., Koshikawa, K., Yla-Herttuala, S., Takahashi, T., & Alitalo, K. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.11.819 · Cited by 521
Metadata
- Authors
- Carmeliet, P., & Jain, R. K.
- Affiliations
- Vlaams Instituut voor Biotechnologie (BE)
- Harvard University (US)
- ORCID
- Carmeliet, Peter
- Venue
- Nature
- Published
- 2000-09
- Volume
- 407
- Issue
- 6801
- Pages
- 249-257
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1573363574
- Cited by
- 9,070
- References
- 72
- Citations by year
- 2026: 166 · 2025: 208 · 2024: 246 · 2023: 330 · 2022: 335 · 2021: 381 · 2020: 368 · 2019: 349 · 2018: 375 · 2017: 380 · 2016: 378 · 2015: 364 · 2014: 414 · 2013: 412 · 2012: 416
- FWCI
- 19.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Keywords
- pathological angiogenesis, cancer, ischemic diseases, inflammatory diseases, anti-angiogenic therapy, clinical trials
- MeSH terms
- Animals, Disease, Humans, Lymphokines, Neoplasms, Neovascularization, Pathologic, Endothelial Growth Factors, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.